Oxford Nanopore Technologies plc

DB:4R0 Stock Report

Market Cap: €1.6b

Oxford Nanopore Technologies Valuation

Is 4R0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4R0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4R0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4R0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4R0?

Key metric: As 4R0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4R0. This is calculated by dividing 4R0's market cap by their current revenue.
What is 4R0's PS Ratio?
PS Ratio8.1x
SalesUK£167.75m
Market CapUK£1.36b

Price to Sales Ratio vs Peers

How does 4R0's PS Ratio compare to its peers?

The above table shows the PS ratio for 4R0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
EVT Evotec
1.8x12.2%€1.4b
GXI Gerresheimer
1.1x9.4%€2.3b
1SXP SCHOTT Pharma KGaA
3.9x9.3%€3.8b
SRT3 Sartorius
5.1x8.8%€15.1b
4R0 Oxford Nanopore Technologies
8.1x22.1%€1.4b

Price-To-Sales vs Peers: 4R0 is expensive based on its Price-To-Sales Ratio (8.1x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does 4R0's PS Ratio compare vs other companies in the European Life Sciences Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
4R0 8.1xIndustry Avg. 4.8xNo. of Companies6PS03.26.49.612.816+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4R0 is expensive based on its Price-To-Sales Ratio (8.1x) compared to the European Life Sciences industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is 4R0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4R0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ratio4.7x

Price-To-Sales vs Fair Ratio: 4R0 is expensive based on its Price-To-Sales Ratio (8.1x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4R0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.70
€2.25
+32.6%
25.3%€3.36€1.34n/a10
Jan ’26€1.50
€2.25
+50.4%
28.4%€3.42€1.21n/a10
Dec ’25€1.81
€2.23
+23.1%
28.4%€3.39€1.20n/a10
Nov ’25€1.57
€2.18
+39.2%
28.8%€3.34€1.18n/a10
Oct ’25€1.97
€2.18
+10.7%
28.8%€3.34€1.18n/a10
Sep ’25€1.38
€2.24
+61.8%
28.0%€3.35€1.19n/a10
Aug ’25€1.57
€2.11
+34.5%
25.0%€2.95€1.18n/a9
Jul ’25€1.14
€2.32
+102.8%
34.4%€4.13€1.18n/a10
Jun ’25€1.24
€2.31
+85.8%
33.8%€4.08€1.17n/a10
May ’25€1.14
€2.34
+106.2%
33.4%€4.06€1.16n/a10
Apr ’25€1.41
€2.58
+82.5%
30.3%€4.10€1.35n/a10
Mar ’25€1.55
€3.10
+99.3%
31.1%€4.67€1.52n/a10
Feb ’25€1.83
€3.28
+79.3%
25.6%€4.67€1.81n/a10
Jan ’25€2.36
€3.61
+53.2%
30.3%€6.13€2.20€1.5010
Dec ’24€2.30
€3.63
+58.1%
30.9%€6.11€2.20€1.8110
Nov ’24€2.40
€3.80
+58.6%
29.2%€6.12€2.20€1.5710
Oct ’24€2.32
€3.92
+68.8%
28.3%€6.14€2.21€1.9710
Sep ’24€2.86
€3.98
+39.2%
26.9%€6.15€2.21€1.3810
Aug ’24€2.90
€4.02
+38.8%
26.7%€6.20€2.23€1.5710
Jul ’24€2.44
€4.02
+64.9%
26.7%€6.20€2.23€1.1410
Jun ’24€3.22
€3.92
+21.8%
28.0%€5.97€1.92€1.2410
May ’24€2.56
€3.92
+53.0%
28.0%€5.97€1.92€1.1410
Apr ’24€2.36
€4.00
+69.2%
28.0%€6.01€1.93€1.4110
Mar ’24€2.31
€4.85
+110.4%
24.8%€7.34€3.05€1.559
Feb ’24€2.80
€5.38
+91.7%
25.1%€7.67€3.54€1.838
Jan ’24€2.77
€6.16
+122.5%
25.0%€8.37€4.65€2.367
Analyst Price Target
Consensus Narrative from 10 Analysts
€2.25
Fair Value
24.5% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/13 12:09
End of Day Share Price 2025/01/13 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oxford Nanopore Technologies plc is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Blanka PorkolabBarclays
Hassan Al-WakeelBarclays
Odysseas ManesiotisBerenberg